Levosalbutamol

Drug Profile

Levosalbutamol

Alternative Names: Levalbuterol; R-albuterol; R-salbutamol; Xopenex; Xopenex HFA; Xopenex MDI®

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sepracor
  • Developer Sepracor; Sunovion Pharmaceuticals
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Phenethylamines; Skin disorder therapies; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease
  • Discontinued Acute asthma

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 21 May 2015 Sunovion terminates phase III trial in Asthma in USA (NCT02150499)
  • 06 Nov 2014 Akorn acquires certain rights to Xopenex® inhalation solution from Sunovion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top